COMBINATION THERAPY FOR CANCER AND AIDS

癌症和艾滋病的联合治疗

• 批准号: 6161015
• 负责人: J N WEINSTEIN
• 金额: --
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6161015
• 关键词: AIDS therapy; antiAIDS agent; antineoplastics; combination chemotherapy; computer data analysis; computer program /software; computer system design /evaluation; data collection methodology /evaluation; drug screening /evaluation; human therapy evaluation; mathematical model; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology; tissue /cell culture; transport inhibitor

This project began with the discovery in our laboratory group of a new possible "modulatory" combination therapy for AIDS (dideoxynucleoside plus nucleoside transport inhibitor), which we and our collaborators developed through Phase I clinical trials. When we could not find any published method appropriate for the design and analysis of our experiments on this combination therapy, we decided to develop our own. The result was a set of new concepts, algorithms, and computer programs, incorporated into a package called COMBO. The COMBO algorithms for design and analysis of combination therapy now form the central portion of this project, albeit a small fraction of overall effort in the research group. We have used the new algorithms and programs (in both cancer and AIDS research) to design and analyze experiments on combinations involving such agents as suramin, tumor necrosis factor, taxol, dipyridamole, AZT, ddI, ddC, CD4-pseudomonas exotoxin, HIV protease inhibitors, and hydroxyurea, among others. Fairly recent published analyses have included those on combinations of AZT or ddi with protease inhibitor KNI-272 (in collaboration with H. Mitsuya and colleagues, AIDS Research and Human Retroviruses 1994;38:1036) and on combinations of dideoxynucleosides and hydroxyurea (in collaboration with R. Gallo and colleagues, e.g., Science 1994;266:801). AIDS title: Combination Therapy for Cancer and AIDS).

这个项目始于我们实验室小组发现的一种新的 艾滋病可能的“调节性”联合疗法(双脱氧核苷 加上核苷转运抑制剂)，我们和我们的合作者 通过I期临床试验开发。当我们找不到任何 发表的方法适用于我们的设计和分析 在对这种联合疗法进行实验后，我们决定开发自己的疗法。 结果产生了一套新的概念、算法和计算机程序， 合并到一个名为COMBO的包中。的组合算法 联合疗法的设计和分析现在构成了核心部分 这个项目的一小部分，尽管只占 课题组。我们已经使用了新的算法和程序(在两个版本中 癌症和艾滋病研究)来设计和分析 涉及苏拉明、肿瘤坏死因子、 紫杉醇，潘生丁，AZT，DDI，ddC，CD4-假单胞菌外毒素，HIV 蛋白水解酶抑制剂和羟基脲等。相当近 已发表的分析包括关于AZT或ddi组合的分析。 使用蛋白酶抑制剂KNI-272(与H.Mitsuya和 同事，艾滋病研究和人类逆转录病毒，1994；38：1036)和 双脱氧核苷和羟基脲的组合(合作 与R.Gallo及其同事，例如，《科学》1994；266：801)。艾滋病标题： 癌症和艾滋病的联合治疗)。